Published
Who actually runs the BFS line
Identify the legal entity that will manufacture and release your product before comparing sales proposals. Ask for its production licence, licence number, site address and the name used on the quotation. Confirm who handles manufacturing, quality decisions and communication, and ask how an on-site or video audit can be arranged. The commercial contact and the factory may be separate companies; the relationship should be explained clearly. Treat refusal to name the proposed site, unexplained changes of entity, or a different factory appearing after sample approval as reasons to stop and clarify the project.
Certificates: numbers, issuer, validity
Check the holder, certificate number, standard, scope, issuer and validity for each document separately. Confirm that the site and activities covered match the proposed production route, and use the issuer’s verification method where one is available. A certificate from another entity or a previous term does not prove current coverage. A third-party cosmetic facility registration record is not an FDA-issued certificate or product approval. Unreadable copies, missing dates, unexplained holders and unsupported renewal claims are warning signs. Request clarification instead of treating a row of certification logos as completed supplier qualification.
Fill-volume accuracy and container integrity
Ask how the agreed fill amount and container integrity are assessed for your actual formula and container. Request the relevant specifications, test methods, sampling approach and release responsibilities, with a suitable record example where access is permitted. Distinguish nominal container capacity from the amount filled and the amount a customer can dispense. Discuss the seal, opening, residual product and secondary protection as part of the finished pack. A statement that a line is automated is not a substitute for agreed acceptance criteria. Missing methods, absent batch traceability or unexplained results need resolution before approval.
Formula compatibility and stability
Review the complete formula–package system rather than accepting a generic statement that an active ingredient suits BFS. Ask how LDPE compatibility, oxidation, appearance, viscosity and dispensing will be evaluated. Agree a stability protocol with relevant conditions and acceptance criteria, and discuss microbial protection or challenge testing where appropriate for the product. Accelerated work must be interpreted within the agreed evidence plan, not sold as a universal shelf-life guarantee. A red flag is a promised finished-product claim based only on an ingredient brochure, a different package or an unrelated formula. Record open tests and approval responsibilities.
MOQ, moulds and what drives cost
Compare quotations on the same formula, fill volume and finished-unit basis. Ask whether the quantity means filled ampoules or assembled kits, whether an existing mould can be used, and which tooling, labels, cartons, inserts, assembly and tests are included. Confirm the quantity per formula and how material availability affects the proposed order. A smaller kit count does not automatically meet a filled-unit MOQ. Treat an unusually low headline quotation with unspecified pack-out, missing tooling or unclear test costs as incomplete. Ask for the same deliverables from each bidder before comparing the final commercial terms.
Lead time: what the quoted days include and exclude
Ask what event starts the quoted schedule and which approvals, materials, tests and logistics sit outside it. Distinguish sample preparation, sample review, production and shipment instead of treating them as one delivery promise. For our standard specifications: Samples: about 7 days. Production: about 15 days. Counted from confirmation of the formula, artwork and packaging materials; standard specifications. Custom molds, new formulas and stability testing are quoted separately. Confirm additional destination-market document work and shipping arrangements separately. A red flag is a fixed delivery claim that ignores an unapproved formula, unfinished artwork, unavailable materials or open test requirements. Record the agreed scope and start point in the quotation.
Documents for your destination market
Agree the document list and responsible parties for the destination before ordering. Ask who issues the relevant COA, SDS or MSDS, packaging specification and permitted batch-record extract, and which stability evidence exists for the actual formula and pack. Confirm when each item becomes available; a future commercial batch cannot have a completed release record at the quotation stage. For EU projects, discuss the information needed by the brand-appointed Responsible Person and safety assessor for the PIF and CPSR. Supplier document support does not transfer those statutory roles. Missing owners or unexplained substitutes are reasons to clarify.
How Steridose Labs answers these seven checks
| Check | Steridose Labs response |
|---|---|
| Manufacturing party | Huaze Ruifu Biotechnology (Guangzhou) Co., Ltd. is our designated manufacturing partner. Guangzhou Maolin Technology Co., Ltd. operates Steridose Labs. The site for your product is named in the quotation. On-site and video audits of the Huaze Ruifu site can be arranged after NDA; scope, dates and attendees are agreed in writing. |
| Certificates and licence | ISO 22716 / GMPC renewal in progress. Production licence 粤妆20230232 states validity through 11 February 2031 in the supplied copy. A facility registration record is not an FDA-issued certificate or product approval. |
| Fill and integrity controls | BFS: 0.5–10 ml. Agree the product specification, test methods, acceptance criteria and applicable records for the selected formula and pack. No unverified accuracy tolerance or test result is claimed. |
| Compatibility and stability | Formula and package assessment precedes approval. Relevant document inputs and available summaries can be provided at the sample stage; additional testing is scoped separately. |
| MOQ and commercial scope | BFS: 10,000 units per formula. Glass ampoules: 1,000–2,000 units. Bottles and jars: quoted per product. Confirm tooling, labels, secondary packaging, assembly and test scope in the quotation. |
| Lead time | Samples: about 7 days. Production: about 15 days. Counted from confirmation of the formula, artwork and packaging materials; standard specifications. Custom molds, new formulas and stability testing are quoted separately. |
| Destination-market documents | Applicable COA, SDS, stability summary, packaging specifications and batch-record extracts on request can be discussed at the sample stage. A COA or record concerns the relevant completed batch. PIF/CPSR input support does not transfer the brand-appointed Responsible Person’s role. |
FAQ
Should I choose a BFS filler from a certificate logo alone?
No. Check the document holder, number, standard, scope, issuer and validity against the proposed manufacturing site. Review the actual copy and use an issuer’s verification route where available. A logo does not establish current coverage for your product.
Can I audit the Huaze Ruifu site?
On-site and video audits of the Huaze Ruifu site can be arranged after NDA. Audit scope, dates and attendees are agreed in writing. The manufacturing site for your product is identified in the quotation.
Do the quoted production days include all development and delivery work?
Samples: about 7 days. Production: about 15 days. Counted from confirmation of the formula, artwork and packaging materials; standard specifications. Custom molds, new formulas and stability testing are quoted separately. Agree any additional destination-market documents and shipment arrangements separately. A production estimate should not be read as a guaranteed delivery date.